Analysis of the Spatiotemporal Development of Hematopoietic Stem and Progenitor Cells in the Early Human Embryo

Jennifer Easterbrook,1 Stanislav Rybtsov,1 Sabrina Gordon-Keylock,1 Andrejs Ivanovs,1,2 Samir Taoudi,3,4,5 Richard A. Anderson,6 and Alexander Medvinsky1,*

1Ontogeny of Haematopoietic Stem Cells Group, Institute for Stem Cell Research, MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK
2Institute of Anatomy and Anthropology, Riga Stradins University, Riga 1007, Latvia
3Molecular Medicine Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052 Australia
4Department of Medical Biology, University of Melbourne, Melbourne, VIC 3052, Australia
5Cancer and Haematology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia
6MRC Centre for Reproductive Health, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TF, UK

*Correspondence: a.medvinsky@ed.ac.uk
https://doi.org/10.1016/j.stemcr.2019.03.003

SUMMARY

Definitive hematopoietic stem cells (HSCs) first emerge in the aorta-gonad-mesonephros (AGM) region in both mice and humans. An ex vivo culture approach has enabled recapitulation and analysis of murine HSC development. Knowledge of early human HSC development is hampered by scarcity of tissue: analysis of both CFU-C and HSC development in the human embryo is limited. Here, we characterized the spatial distribution and temporal kinetics of CFU-C development within early human embryonic tissues. We then sought to adapt the murine ex vivo culture system to recapitulate human HSC development. We show robust expansion of CFU-Cs and maintenance, but no significant expansion, of human HSCs in culture. Furthermore, we demonstrate that HSCs emerge predominantly in the middle section of the dorsal aorta in our culture system. We conclude that there are important differences between early mouse and human hematopoiesis, which currently hinder the quest to recapitulate human HSC development ex vivo.

INTRODUCTION

Hematopoietic stem cells (HSCs) develop in the aorta-gonad-mesonephros (AGM) region, marking the onset of life-long adult hematopoiesis (Ivanovs et al., 2011; Medvinsky and Dzierzak, 1996; Müller et al., 1994). Various lines of evidence indicate that in both mice and humans, HSCs mature within intra-aortic hematopoietic clusters (IAHCs), budding predominantly from the ventral floor of the dorsal aorta, and co-express endothelial and hematopoietic markers: CD34, CD144 (VE-cadherin), CD45, RUNX1 (Ivanovs et al., 2014; Souilhol et al., 2016; Tavian et al., 1996, 1999; Taylor et al., 2010; Yokomizo and Dzierzak, 2010). In mouse and humans, definitive HSCs, detectable by direct transplantation into adult recipients, emerge in the AGM region in low numbers (~1 HSC) (Ivanovs et al., 2011; Kumaravelu et al., 2002; Rybtsov et al., 2016).

Knowledge of the process of HSC maturation and expansion will be essential for directing the successful development of HSCs in vitro. Due to the rarity of suitable embryonic material, analysis of early HSC development in humans has significantly lagged behind mouse studies. In the mouse, an AGM ex vivo culture system facilitates recapitulation of HSC development, enabling the analysis of the developing HSC hierarchy and identification of HSC molecular regulators (Rybtsov et al., 2011, 2014; Souilhol et al., 2016; Taoudi et al., 2008). This culture system, functionally validated by long-term repopulation transplantation assays, has demonstrated a concealed dramatic expansion of immature HSC precursors (pre-HSCs) that occurs in the mouse AGM region prior to colonization of the fetal liver (Rybtsov et al., 2016). Evidence of human precursors of HSCs has not yet been sought. We hypothesized that pre-HSCs also exist in the human AGM and that their existence could be established using similar culture conditions to those employed for the maturation of mouse HSCs.

Understanding the precise location of HSC emergence will also be fundamental for future investigation of human embryonic hematopoiesis and ultimately achieving the generation of HSCs in vitro. Earlier studies in the human embryo demonstrated that IAHCs, composed of hematopoietic CD34+CD45+ cells, are found exclusively in the ventral side of the dorsal aorta (AoV), emerging at Carnegie stage (CS) 12–13 (27 days post conception [dpc]) and disappearing by CS17 (39–42 dpc) (Tavian et al., 1996, 1999). This exclusive location of clusters in AoV correlates with the detection of HSCs only in AoV in the human embryo (Ivanovs et al., 2011). We hypothesized that the location of HSCs would also correlate with the distribution of hematopoietic progenitor cells in the AGM region. Basic analysis of committed human myeloid progenitor cells (CFU-Cs) in the human embryo...
is currently limited (Huyhn et al., 1995; Tavian et al., 2001). Here, we aimed to advance our understanding of early human hematopoietic development by temporal and spatial characterization of CFU-Cs and HSCs generated during the period of embryonic development between CS14 and CS17, when definitive HSCs and IAHCs are detectable in the human AGM region (Ivanovs et al., 2011; Tavian et al., 1996, 1999). We also aimed to establish a human AGM culture system, similar to the mouse system, which would recapitulate the in vivo process of HSC maturation and potentially reveal the presence of human pre-HSCs. We focused on a major regulator of HSC development, stem cell factor (SCF, KIT ligand) expressed in the AGM region, which efficiently supports HSC maturation in mouse AGM explants (Rybtsov et al., 2014; Souilhol et al., 2016).

We present quantitative distribution and growth kinetics of CFU-C development across hematopoietic tissues. The analysis of the ex vivo culture of the human AGM regions showed robust CFU-C expansion, but minimal or no HSC maturation/expansion. Although we revealed that definitive HSCs emerge predominantly in the middle section of the dorsal aorta, the failure to establish a productive human AGM culture system prevents us currently from gaining insight into human pre-HSC development. We conclude that despite clear evolutionary conservation of hematopoietic development across vertebrate species, some important differences between mouse and human exist that currently hinder analysis of HSC development in the human AGM region.

RESULTS

Spatial and Temporal Distribution of Hematopoietic Progenitors in the Early Human Embryo

To establish the spatial and temporal distribution of hematopoietic progenitors during early human development, we performed CFU-C assays during and just before the developmental window for HSCs/IAHCs in the human AGM region (CS12–17). CFU-Cs in the AGM region showed a linear increase in total numbers from 75 ± 35 at CS12 to 700 ± 340 at CS17 (Figure 1). In the yolk sac, total CFU-C numbers remained more constant throughout this period (400 ± 140 at CS12 and 375 ± 75 at CS17). Meanwhile, in the embryonic liver, low CFU-C numbers (range, 40–210) were observed until CS14, followed by a dramatic rise at CS 15/16 (range, 700–1,100) with a further increase at CS17 (2,500). CFU-C numbers in the umbilical cord were low at all stages and fluctuated between 60 (at CS12) and 200 (at CS16). Notably, the size of myeloid colonies from the AGM region appeared larger than from other embryonic tissues (Figure S1).

With regard to colony morphology, CFU-Cs both in the AGM region and the yolk sac were predominantly granulocyte/macrophage (myeloid) colonies and a sizable fraction of relatively large erythroid colonies. A slight increase in erythroid colonies in the yolk sac occurred concurrently with their peak in the embryonic liver, AGM, and umbilical cord at CS16, potentially consistent with colonization of the embryo body with yolk sac progenitors. We also observed an increased complexity of colonies generated.
by livers from CS15 to CS17 with progressive appearance of mixed colonies (CFU-MIX) representing more immature progenitors (Figure 1). This was not observed in other tissues including the AGM region.

Establishing a Human AGM Explant Culture System

For the explant culture, AGM regions were dissected and cultured for 7 days in the presence of 100 ng/mL SCF (Figure 2), based on its efficient support of HSC maturation in the mouse AGM region (Rybtsov et al., 2014). We observed a 7.7-fold increase (range, 3.3–12.8) in CFU-C numbers across all CS13-17 AGM explants (n = 7). The number of CFU-Cs before culture was taken from other independent experiments since explants cannot be disrupted prior to culture (Figure 1A). We noted the appearance of CFU-MIX in cultured AGM regions that were not present before culture, suggesting their generation in explants. The macroscopic appearance of other types of colonies before and after culture was similar (Figure S1). Explants of other embryonic tissues (umbilical cord, yolk sac, liver) also showed expansion of CFU-Cs ranging from a mean fold change of 5 for the umbilical cord to 11 for the yolk sac across all experiments (Figure S3).

We next tested whether human HSCs could mature in the AGM culture. Between CS14 and CS17, the AGM region contains ~1 definitive HSC, which can provide long-term multilineage hematopoietic engraftment in NSG mice upon transplantation (Ivanovs et al., 2011). Initial independent experiments (n = 4) were performed using the whole AGM region or anterior and posterior halves (cut along the rostra-caudal axis) in the presence of exogenous SCF (Table 1; Experiments A–D). After 7 days of culture,
AGM explants were dissociated and injected intravenously into irradiated NSG mice. Every 1–2 months post transplantation, the peripheral blood of recipient animals was assessed for donor-derived hematopoietic contribution using a combination of anti-mouse and anti-human CD45 antibodies. Multilineage engraftment was assessed for donor-derived hematopoietic contribution using a combination of anti-mouse and anti-human CD45 antibodies. Multilineage engraftment was assessed

### Table 1. Analysis of Long-Term Repopulation of NSG Mice by Cultured Human AGM

<table>
<thead>
<tr>
<th>CS</th>
<th>AGM Region</th>
<th>Conditions</th>
<th>Embryonic Equivalent/Mouse</th>
<th>No. Engrafted/No. Injected</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Initial Experiments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>15 Anterior</td>
<td>SCF 300</td>
<td>0.14</td>
<td>0 + 3/3</td>
</tr>
<tr>
<td></td>
<td>15 Posterior</td>
<td>SCF</td>
<td>0.14</td>
<td>0 + 3/3</td>
</tr>
<tr>
<td>B</td>
<td>16 Anterior</td>
<td>SCF</td>
<td>0.5</td>
<td>1/2</td>
</tr>
<tr>
<td></td>
<td>16 Posterior</td>
<td>SCF</td>
<td>0.5</td>
<td>0/2</td>
</tr>
<tr>
<td>C</td>
<td>17 Anterior</td>
<td>SCF, TGF-βi, ROCKi</td>
<td>0.28</td>
<td>0 + 3/3</td>
</tr>
<tr>
<td></td>
<td>17 Posterior</td>
<td>SCF</td>
<td>0.28</td>
<td>3/3</td>
</tr>
<tr>
<td>D</td>
<td>17 Whole AGM</td>
<td>SCF, TGF-βi, ROCKi</td>
<td>0.15</td>
<td>1/6</td>
</tr>
<tr>
<td></td>
<td>Mapping Experiments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E</td>
<td>13 Part 1</td>
<td>SCF</td>
<td>0.96</td>
<td>0/1</td>
</tr>
<tr>
<td></td>
<td>13 Part 2</td>
<td>SCF</td>
<td>0.96</td>
<td>1/1</td>
</tr>
<tr>
<td></td>
<td>13 Part 3</td>
<td>SCF</td>
<td>0.96</td>
<td>0/1</td>
</tr>
<tr>
<td></td>
<td>13 Part 4</td>
<td>SCF</td>
<td>0.96</td>
<td>0/1</td>
</tr>
<tr>
<td>F</td>
<td>16 Part 1</td>
<td>SCF</td>
<td>0.96</td>
<td>0/1</td>
</tr>
<tr>
<td></td>
<td>16 Part 2</td>
<td>SCF</td>
<td>0.96</td>
<td>1/1</td>
</tr>
<tr>
<td></td>
<td>16 Part 3</td>
<td>SCF</td>
<td>0.96</td>
<td>1/1</td>
</tr>
<tr>
<td></td>
<td>16 Part 4</td>
<td>SCF</td>
<td>0.96</td>
<td>0/1</td>
</tr>
<tr>
<td>G</td>
<td>16 Part 1</td>
<td>SCF</td>
<td>0.3</td>
<td>0/2</td>
</tr>
<tr>
<td></td>
<td>16 Part 2</td>
<td>SCF</td>
<td>0.3</td>
<td>1 + 1/2</td>
</tr>
<tr>
<td></td>
<td>16 Part 3</td>
<td>SCF</td>
<td>0.3</td>
<td>1/3</td>
</tr>
<tr>
<td></td>
<td>16 Part 4</td>
<td>SCF</td>
<td>0.3</td>
<td>0/3</td>
</tr>
<tr>
<td>H</td>
<td>16 Part 1</td>
<td>SCF</td>
<td>0.3</td>
<td>0/3</td>
</tr>
<tr>
<td></td>
<td>16 Part 2</td>
<td>SCF</td>
<td>0.3</td>
<td>2/3</td>
</tr>
<tr>
<td></td>
<td>16 Part 3</td>
<td>SCF</td>
<td>0.3</td>
<td>0/2</td>
</tr>
<tr>
<td></td>
<td>16 Part 4</td>
<td>SCF</td>
<td>0.3</td>
<td>0/3</td>
</tr>
<tr>
<td>I</td>
<td>17 Part 2</td>
<td>SCF</td>
<td>0.3</td>
<td>1 + 1/2</td>
</tr>
<tr>
<td></td>
<td>17 Part 3</td>
<td>SCF</td>
<td>0.3</td>
<td>1/1</td>
</tr>
<tr>
<td></td>
<td>17 Part 4</td>
<td>SCF</td>
<td>0.3</td>
<td>1/2</td>
</tr>
</tbody>
</table>

The number of repopulated NSG mice relative to the number of mice injected and analyzed are shown. For example, 1 + 1/2 means one of the two mice injected had long-term multilineage repopulation at >1%; in the other mouse low-level engraftment was detected. Parts 1–4 are described in Figure S2 and experiments correspond to those in Tables 2 and 3. The embryo equivalent (ee) received by each mouse refers to the ee of each part of the AGM region. SCF is 100 ng/mL unless stated as 300 (ng/mL), TGF-β inhibitor 5 μM, ROCK inhibitor 10 μM, FLT3LG 100 ng/mL. CS, Carnegie stage. TGF-βi, TGF-β inhibitor. ROCKi, ROCK inhibitor.

aLow level (<1%) engraftment in bone marrow.
bFull multilineage analysis not performed.
in blood, bone marrow, and spleen at least 3 months post transplantation. From a total of 22 recipients, five were reconstituted with >1% human CD45+ cells and nine recipients had only low level (<1%) of bone marrow engraftment with no engraftment in peripheral blood. In one variant included in these experiments, one cultured posterior half of a CS17 AGM region showed >1% engraftment of three recipients, which is more than is expected before culture (Table 1, Experiment C). In two of the experiments with CS17 AGM regions, we used transforming growth factor β (TGF-β) inhibitor (5 mM) and ROCK inhibitor (10 mM) as these might improve the outcome, but these cultures showed no clear benefit compared with SCF only cultures (Table 1, Experiments C and D). Overall, the frequencies of repopulation showed that in contrast to mouse AGM culture systems, human AGM explants failed to support HSC maturation (expansion), but rather showed maintenance of solitary definitive HSCs pre-existing in fresh AGM region (Ivanovs et al., 2011). It is unclear whether one case of repopulation of three recipients by a single half of cultured CS17 AGM region (Table 1, Experiment C) was a result of unusually high contents of definitive HSCs (three or more) in the fresh tissue, or because in this particular case some HSC maturation occurred.

Explants of other embryonic tissues obtained from the same embryos (yolk sac, umbilical cord, and vitelline arteries) have not shown the presence of definitive HSCs after transplantation into NSG mice (cultures in the presence of SCF, TGF-β inhibitor, ROCK inhibitor, and/or FLT3 ligand [FLT3LG]) (Table S1). For cultured explants of embryonic livers, three of three NSG recipients had low-level bone marrow engraftment in two independent experiments (Table S1, Experiments C and H, CS16 and CS17), and in one independent experiment, long-term multilineage was observed (CS17) (Table S1, Experiment I), suggesting the possible beginning of liver colonization at this stage.

**Hematopoietic Capacity of Self-Reaggregate and Co-aggregate Cultures**

Self-reaggregate and co-aggregate cultures of the AGM region have been a powerful method for analysis of mechanisms underlying HSC development in the mouse AGM region (Rybtsov et al., 2011, 2014; Souilhol et al., 2016; Taoudi et al., 2008). Here, for the self-reaggregate cultures, single-cell suspensions of CS14–17 AGM regions were reaggregated (10^5 cells/reaggregate) and cultured in the presence of SCF, interleukin 3 (IL3), FLT3LG (50 ng/mL each) for 5 days. In contrast to explants, dissociation of cells enabled multiple aliquots to be prepared from one embryo and therefore direct comparison of CFU-C numbers in fresh tissues and after culture. Similar to explant cultures, CFU-C numbers increased 7.7-fold (range, 3.2–12.4) (Figure 2C).

For co-aggregate cultures, 10^5 AGM cells obtained from CS12–17 AGM regions were aggregated with 10^5 OP9 cells and cultured with SCF and IL3 (100 ng/mL each) for 7 days. We observed an 18.6-fold increase (range, 8.0–31.1) in CFU-C numbers after 7 days in co-aggregates across all experiments, which is higher than with both self-reaggregate and explant cultures (Figures 2D and 2E).

We then performed eight independent experiments where CS12–17 AGM regions were self-reaggregated and after being cultured for 7 days, were transplanted into irradiated NSG recipients. Only in one experiment were we able to detect long-term repopulation (data not shown). In a further six independent experiments, we performed co-aggregation of the CS12–17 AGM region with OP9s for 7 days in the presence of exogenous SCF and IL3 100 ng/mL. None of the experiments gave long-term hematopoietic reconstitution of NSG mice after transplantation (data not shown).

**Definitive HSCs Are Localized Mainly to the Central Portion of the Human AGM Region**

HSCs are known to emerge from the ventral side of the dorsal aorta (Ivanovs et al., 2014) but their more precise location along the rostro-caudal axis remains unknown. To clarify this, the AGM region was sub-dissected into four parts along the rostro-caudal axis as outlined in Figure S2. Part 1 was cut above the urogenital ridges (UGRs) and included the aortic bifurcation. Part 2 was cut from above the vitelline artery/superior mesenteric artery (VA/SMA) to the rostral border of the UGRs (the superior mesenteric artery is a derivative of the vitelline artery and supplies the mid gut; Schoenwolf et al., 2014). Part 3 was cut above the umbilical artery (UA) entry points and included the VA/SMA, and part 4 included the UA entry points and aorta below. Each sub-section of the AGM region was cultured as an explant in the presence of SCF 100 ng/mL and after 7 days transplanted into irradiated adult NSG recipients.

In four of these five independent “mapping” experiments, HSCs could be detected in AGM regions after culture (Table 1, Experiments E-I). In all successful experiments, HSCs were found in parts 2 and 3, i.e., around and above the VA/SMA limited by the rostral border of the UGRs. In one of these experiments, an additional HSC was also found in part 4, around the UA entry points. Interestingly, it seems that we had a slight expansion of HSC numbers in these experiments. Three of four cultured CS16–17 AGM regions contained two or three HSCs, which is higher than expected in fresh AGM regions (Ivanovs et al., 2011). Similarly, we have been able to detect the appearance of a definitive HSC after transplantation of part 2 of a CS13 embryo, which has not previously been detectable in the AGM region at this stage.
To establish the relative location of CFU-C production in the AGM region, a small aliquot, no greater than 0.1 embryo equivalent (ee), was taken from the single-cell suspension made from embryonic tissues 7 days after culture (the rest was used for transplantations into NSG mice as described above; Table 1). The aliquot was used for the hematopoietic CFU-C assay. Results from six independent experiments from CS13–17 are shown in Figure 3. Parts 2 and 3 contained the highest numbers of CFU-Cs in all six experiments (range, 780–4,600), except for the CS13 experiment where part 1 was found to have the most CFU-Cs. HSCs were also consistently present in parts 2 and 3 (Figure 3 and Table 1). In all six experiments, the lowest CFU-C numbers (≤210 per 1 embryo equivalent [ee]) were detected around the UA entry points. Thus, the location of the highest CFU-C numbers correlated with the positions in which HSCs were detected. In all experiments, except CS13 analysis, mixed colonies were
Explant Culture Maintains HSCs with Long-Term Multilineage In Vivo Repopulating Capacity

In NSG mice repopulated with cultured human AGM, engraftment could first be detected in the peripheral blood of mice at around 8 weeks (0.14% ± 0.1%), and in most there was a notable rise in engraftment level at 4–5 months (Figure 4A). Levels of engraftment ranged from 1.6% (12 weeks) to 49.7% (17 weeks) in the bone marrow, 0.1% (12 weeks) to 10% (17 weeks) in the blood, and 0.4% (12 weeks) to 20.8% (20 weeks) in the spleen (Table 2). The one NSG recipient successfully engrafted with cultured embryonic liver had relatively higher engraftment at 21 weeks compared with those transplanted with the human AGM with 22% in blood, 23.4% in bone marrow, and 23.9% in the spleen (Table 2). As expected, across all samples, human multilineage hematopoietic repopulation generally displayed a B lymphoid bias in engrafted NSG mice (Ivanovs et al., 2011; Shultz et al., 2005; Theocharides et al., 2016). Human CD19+ B cells were the major human leukocyte population in the peripheral blood (55% ± 18%) and spleen (58% ± 24%). However, in the bone marrow, the major human leukocyte population was more variable, in some mice being B lymphoid-biased (9/13 mice; mean, 52% ± 24%) and in others myeloid-biased (4/13 mice; mean, 37% ± 22%) (Table 3, Figures 4B and S4). Human CD33+CD66b+ granulocytes and CD33+CD14+ macrophages were also detected in blood, bone marrow, and spleen of engrafted NSG mice (Table 3, Figures 4B, 4C, and S4). The level of human CD3+ T cells and CD94+ NK cells was particularly variable, as had been seen with the transplantation of fresh AGM into NSG mice (Ivanovs et al., 2011). Human immunophenotypic HSCs

Figure 4. Explant Culture Maintains HSCs with Long-Term Multilineage Repopulating Capacity In Vivo
(A) Kinetics of human hematopoietic repopulation in the peripheral blood for 14 NSG mice transplanted with cultured human AGM (solid lines) or embryonic liver (EL) (dotted line).
(CD34⁺CD38⁻CD90⁺CD45RA⁻), multipotent progenitors (MPPs) (CD34⁺CD38⁻CD90⁺CD45RA⁻), and multi-lymphoid progenitors (MLPs) (CD34⁺CD38⁻CD90⁻CD45RA+) could be identified in the recipient bone marrow (Figure 4 C) (Doulatov et al., 2010; Majeti et al., 2007), constituting 12% ± 4%, 13% ± 4%, 23% ± 7% of CD34⁺ cells, respectively. Comparing these proportions with human bone marrow (BM) and cord blood (Doulatov et al., 2010; Majeti et al., 2007), MLPs were the dominant population of hematopoietic progenitors in the recipient BM rather than MPPs.

DISCUSSION

The AGM region is the major site of HSC development in mammals. The first HSCs emerge in low numbers (as single cells), both in the mouse and human dorsal aorta (Ivanovs et al., 2011; Kumaravelu et al., 2002; Müller et al., 1994). It had previously been shown that the first HSCs emerge from the ventral side of the dorsal aorta at CS14–17 in the human embryo (Ivanovs et al., 2014). However, their more precise location along the rostral-caudal axis and relationship to CFU-Cs remains unexplored. In addition, the developing human HSC hierarchy has yet to be established.

While an ex vivo culture system has facilitated recapitulation of HSC development in the mouse and been pivotal in our understanding of the mouse developmental HSC hierarchy, this system has not yet been translated into human studies (Rybtsov et al., 2011, 2014; Souilhol et al., 2016; Taoudi et al., 2008). We therefore sought to advance understanding of early human hematopoietic development by temporal and spatial characterization of CFU-Cs and HSCs through adaption of the murine ex vivo culture system for the human AGM region. A previous study described the distribution of CFU-Cs in the extra-hepatic embryo but did not specifically describe CFU-Cs in the AGM (Huyhn et al., 1995).

We observed significant numbers of CFU-Cs initially in the yolk sac from CS12. Meanwhile, the AGM region was only gradually accumulating CFU-C numbers in line with the role of the yolk sac in the colonization of the AGM region established for the mouse (McGrath et al., 2015; Palis et al., 1999). Interestingly, we observed a sharp rise in CFU-C content in the liver beginning from CS15, consistent with previous studies (Huyhn et al., 1995; Tavian et al., 1996, 1999). It is not currently clear whether it is related to changes in CFU-C properties or critical development of the liver stroma. Notably, we observed the appearance of immature CFU-MIX in the liver from CS16.
but not in other tissues (without culture), consistent with the role of the liver in the development of definitive hematopoiesis. Future analysis will be needed to determine what proportion of CFU-Cs circulating during these stages are erythro-myeloid progenitors (McGrath et al., 2015) and which of them are multipotent ones with lymphoid potential. Based on analysis of the mouse model, we can assume that the human AGM region contains a number of immature precursors of definitive HSCs (Rybtsov et al., 2011, 2014; Taoudi et al., 2008). In line with that, AGM cultures start producing CFU-MIX, which are absent in the fresh tissue.

HSC precursors are unable to engraft when directly transplanted into an adult recipient, but can engraft when allowed to mature in culture to become HSCs. Our adaption of the murine *ex vivo* culture system failed to convincingly reveal HSC precursors but has hinted at their existence. We established that up to three HSCs can be detected after 7 days of explant culture of the human AGM region, which at least matches and potentially surpasses the one or two HSCs detected in the fresh AGM region (Ivanovs et al., 2011). In the current experiments, we frequently detected at least two HSCs per AGM region, suggesting some limited maturation of HSC precursors in the explant culture system. Indeed, it seems unlikely that this slight effect was due to self-renewal of pre-existing definitive HSCs, since after culture, HSCs were generally present in separate AGM sub-sections. Although experiments directly comparing cultured and uncultured AGM would have helped to answer whether the culture system did indeed mature any precursors of HSCs, such experiments are not possible due to the scarcity of human embryonic tissue. Although the aggregate culture system could address this issue, we found no repopulation after aggregate culture of human AGM region.

HSCs derived from explant cultured human embryonic tissue provided long-term multilineage repopulation of NSG mice as was observed with fresh AGM region (Ivanovs et al., 2011). Variability in the distribution of lineages engrafted was detected, in line with our previously reported transplantation of AGM region cells directly into NSG mice (Ivanovs et al., 2011). This may reflect individual differences in the repopulating capacity of NSG mice or the lineage bias of individual HSCs transplanted. Proportions of progenitor populations in the BM of repopulated mice differed from those previously reported for fresh BM and cord blood (Doulatov et al., 2010; Majeti et al., 2007). Again, further work would be required to investigate

### Table 3. Multilineage Hematopoietic Engraftment in Primary Recipient Mice

<table>
<thead>
<tr>
<th>Experiment No. (CS)</th>
<th>Tissue</th>
<th>Blood (%)</th>
<th>Bone Marrow (%)</th>
<th>Spleen (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Myeloid</td>
<td>B</td>
<td>T</td>
</tr>
<tr>
<td>B (16) Anterior</td>
<td></td>
<td>28</td>
<td>30</td>
<td>40</td>
</tr>
<tr>
<td>C (17) Posterior</td>
<td></td>
<td>29</td>
<td>69</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>25</td>
<td>70</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7</td>
<td>45</td>
<td>45</td>
</tr>
<tr>
<td>D (17) Whole</td>
<td></td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>F (16) Part 2</td>
<td></td>
<td>8</td>
<td>61</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>20</td>
<td>46</td>
<td>NA</td>
</tr>
<tr>
<td>G (16) Part 2</td>
<td></td>
<td>51</td>
<td>39</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>33</td>
<td>17</td>
<td>33</td>
</tr>
<tr>
<td>I (17) Part 2</td>
<td></td>
<td>10</td>
<td>72</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td></td>
<td>36</td>
<td>47</td>
<td>1.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16</td>
<td>61</td>
<td>2.0</td>
</tr>
<tr>
<td>Liver</td>
<td></td>
<td>12</td>
<td>22</td>
<td>48</td>
</tr>
</tbody>
</table>

Percentage of myeloid cells (CD33*), B cells (CD19*), T cells (CD3*), and NK cells (CD94*) in the human CD45* cell population in the peripheral blood, bone marrow, and spleen of repopulated primary recipient NSG mice is shown. Only repopulated mice are shown and correspond to engrafted mice indicated in Tables 1 and 2. The NSG mouse engrafted with embryonic liver is included for completeness. NA, not assessed.
whether this is due to unique properties of human embryonic HSCs, the repopulating capacity of NSG mice, or both. It was noted that the absolute levels of human engraftment reported here were slightly lower than those previously reported for human AGM directly transplanted into NSG mice without being cultured (Ivanovs et al., 2011). Given the time between the studies, this may reflect many variables, including the individual NSG mice. However, it could reflect a real reduction in the repopulating capacity of the HSCs after culture.

In terms of spatial distribution, this study has shown that HSCs are chiefly located around and above the vitelline artery entry point to the rostral end of UGRs. HSCs in the E11 mouse AGM region were also found to be enriched in the middle portion of the aorta, near the junction of the dorsal aorta and vitelline artery (Mascarenhas et al., 2009). Notably, these AGM portions possess the capacity to produce large numbers of CFU-Cs in our experiments. It is also interesting that this area of the human AGM region is known to be enriched for IAHCs (Tavian et al., 1996, 1999). Nonetheless, correlation between IAHCs and HSC activity is not direct; by CS17, IAHCs largely disappear, while HSCs are still detectable (Ivanovs et al., 2011; Tavian et al., 1999). Here, we show that CFU-C productivity in the AGM region increased in a linear manner throughout CS12–17, while the IAHCs decline by CS17. This may be due to migration of progenitors from the yolk sac via the vitelline artery and colonization in the AGM region. However, further work would be required to examine this hypothesis.

This work poses the question of why this ex vivo culture system does not facilitate the large-scale maturation and expansion of human HSCs seen for mouse HSCs, given the robustness of the mouse AGM culture system. The most likely explanation is that the culture system has not been optimized. Given the significantly longer timescale of human development (Ivanovs et al., 2017), HSC maturation may require more than the 7 days that we were testing in these experiments. Additionally, here we chose factors based on mouse ex vivo culture studies (Robin et al., 2006; Taoudi et al., 2008). In spite of significant conservation of hematopoietic development across vertebrate species, there might be differences in requirement of cytokines between mouse and human.

In summary, we established that human AGM-derived definitive HSCs can be maintained and on rare occasions mature from HSC precursors in culture. This work enhances our understanding of the spatial development of HSCs, localizing them predominantly to the portion of the AGM region around and above the vitelline artery, which shows high CFU-C productivity, and which are enriched for intra-aortic clusters. Our study highlights important differences in the biology of human and murine embryonic hematopoietic development, which are yet to be unraveled.

We believe the search for conditions to support human HSC development in human AGM culture should continue, as this would greatly assist the derivation of transgene-free clinically applicable HSCs from human embryonic/induced pluripotent stem cells.

**EXPERIMENTAL PROCEDURES**

**Processing of Human Embryonic Tissue**

Human embryos were obtained immediately after elective termination of pregnancy either from the Royal Infirmary of Edinburgh (RAA/FT study, approved by the Lothian Research Ethics Committee, Reference: 08/S1101/1) or from the MRC-Wellcome Trust Human Developmental Biology Resource (HDBR), Institute of Genetic Medicine, Newcastle. All patients donating tissue had given informed written consent for the use of human embryonic tissues in research prior to tissues being obtained and anonymized. The developmental stage of human embryos was determined by the CS system (Ivanovs et al., 2013; O’Rahilly and Muller, 1987).

Dissections were performed under a low power stereomicroscope (Leica MZ8) in sterile dissection buffer (Dulbecco’s phosphate buffered saline [PBS] with Mg2+ and Ca2+ ions [Sigma-Aldrich] containing 7% fetal calf serum [FCS] [Thermo Fisher Scientific or APS], 100 IU/mL penicillin and 100 µg/mL streptomycin [Invitrogen]). Where possible, the AGM region, yolk sac, umbilical cord, vitelline vessels, and liver were obtained from each embryo. However, due to damage to the embryo prior to obtaining them, it was not always possible to harvest all tissues. Further sub-dissection of the AGM region is described in the Results. Images of human tissue were taken using a Leica MZ FLIII with DFC7000T camera (Leica). Embryonic tissues were dissociated to single-cell suspensions in 5 mL polystyrene tubes (BD Falcon). For this, 800 µL of dissection buffer was used with 100 µL of 10 mg/mL collagenase-dispase (Roche) and 100 µL of 1.2 mg/mL DNase I (Roche) and incubated at 37°C for 40 min with gentle shaking in a water bath. The dissociation was stopped by adding 4 mL of dissociation buffer (Dulbecco’s PBS without Mg2+ and Ca2+ [Sigma-Aldrich] containing 7% FCS and 100 IU/mL penicillin and 100 µg/mL streptomycin), centrifugation at 350 × g for 5 min at 4°C and resuspending in flow cytometry buffer (Dulbecco’s PBS without Mg2+ and Ca2+ containing 2% FCS with or without 100 IU/mL penicillin and 100 µg/mL streptomycin) in a suitable volume for further analysis or culture. The number of cells was quantified as embryo equivalents. “Independent” experiments refers to those performed with different human embryos.

**Human Embryo Culture System**

Human embryonic tissues were cultured both as explants and aggregates in Costar tissue culture 6-well plates in embryo culture medium (Iscove’s modified Dulbecco’s medium [IMDM; Gibco], 20% pre-selected heat-inactivated Hyclone FCS [Thermo Fisher Scientific], L-glutamine [4 mM, Invitrogen], 100 IU/mL penicillin and 100 µg/mL streptomycin). The culture was performed at the liquid-gas interface on 0.8-µm nitrocellulose filters (Millipore).
collagenase/dispase as outlined for fresh embryonic tissues and explants and aggregates were harvested and dissociated with no. SCM075). Details are described in the Results section. Both 10^6 Stem Cell Reports 1 3
Stem Cell Reports
10^6 OP9 stromal cells were first obtained by trypsinization and mixed in the Medvinsky group. Where co-aggregates were being made, L-glutamine (4 mM), penicillin/streptomycin (50 U/mL) and passaged every 4–5 days. They had previously been maintained with a single-cell suspension of embryonic tissue (1 \times 10^3 OP9s + 1 \times 10^3 human embryonic cells/aggregate). For self-reaggregates, 1 \times 10^2 embryonic cells were used per aggregate. Two to three aggregates were placed on each membrane. Reaggregates or co-aggregates were formed by centrifugation of cell suspensions at 440 \times g for 12 min in 200-μL pipette tips sealed with parafilm to form a pellet (Taouidi et al., 2008). Experimental variables for the culture medium included addition of human SCF 100–300 ng/mL (catalog no. 300-07), IL3 100 ng/mL (catalog no. 200-03), FLT3LG 100 ng/mL (catalog no. AF-300-19) (all Peprotech), TGF-β inhibitor (SB 431542) 5 μM (Tocris, catalog no. 1614), ROCK inhibitor Y-27632 10 μM (Sigma-Aldrich, catalog no. SCM075). Details are described in the Results section. Both explants and aggregates were harvested and dissociated with collagenase/dispase as outlined for fresh embryonic tissues and used for further analysis.

In Vivo Long-Term Repopulation Assay
NOD.Cg-Prkdcsclid Il2rgtm1Wjl (NSG) mice were used as recipients of human cells. All experiments with animals were performed under a project license granted by the Home Office (UK), University of Edinburgh Ethical Review Committee, and conducted in accordance with local guidelines. Animals were bred and housed within the University of Edinburgh under the regulations of the Animals Scientific Procedures Act, UK, 1986. The NSG mice were housed in pathogen-free conditions in individually ventilated cages or isolators. They received autoclaved drinking water, autoclaved bedding, and γ-irradiated chow diet. For the first 4 weeks after irradiation, their autoclaved drinking water was supplemented with 0.1 mg/mL of enrofloxacin (10% Baytril solution from Bayer). All mice were exposed to a constant cycle of 14 h of light/10 h of dark. Up to 6 h prior to transplantation with human cells, 6- to 8-week-old NSG mice received a sublethal dose of total body irradiation (3.3 Gy at a rate of 0.75 Gy/min from a 137Cs source [GSR D1 γ-irradiator, Gamma-Service Medical]). Animals were transplanted with cells intravenously through the lateral tail vein in up to 200 μL using a 26-gauge syringe needle (BD Microlance), according to the procedures described in the project license and the regulations of the Animals Scientific Procedures Act, UK, 1986. Where human embryonic tissue was used, the quantity of human embryonic tissue transplanted is expressed in embryo equivalents, which is the number of cells present in a whole or specified part of an embryo of that stage.

As a positive control for selected experiments, 4 \times 10^4 UCB CD34+ cells were injected intravenously. Human UCB samples were obtained from full-term umbilical cord after elective cesarean sections from the Edinburgh Reproductive Tissue Biobank. This study was approved by the Lothian Research Ethics Committee (reference, 16/SS/0220). All patients donating tissue had given informed written consent for the use of human tissues in research prior to tissues being obtained and anonymized. Erythrocytes were lysed with BD Pharm Lyse Buffer (BD Biosciences). CD34+ cells were sorted by magnetic cell separation using CD34 microbeads, a QuadroMACS separator, and LS columns (MACS Miltenyi Biotec) according to the manufacturer’s instructions. After selection, cells were stored at −150°C.

To detect long-term hematopoietic repopulation, NSG recipient mice were bled every 1–2 months starting from 6–8 weeks after transplantation. Their tail vein was nicked and 2–3 drops collected into flow cytometry buffer supplemented with 5 mM of EDTA (VWR International). Red cells were lysed using BD Pharm Lyse Buffer (BD Biosciences) diluted 1:10 with water, and flow cytometry was performed to assess for human engraftment with anti-human CD45 antibody. Experiments were ended at 3–8 months after transplantation. All recipient mice were killed by dislocation of the neck according to Schedule 1 of the Animal (Scientific Procedures) Act 1986, and their BM (long bones), spleen, and thymus were harvested. Spleen and thymus were gently mashed in a small volume of buffer through a 40 μm EASYstrainer (Greiner Bio-One). The BM was flushed out from the bones, and a single-cell suspension was prepared by gentle pipetting. Cell suspensions of BM, thymus, and spleen were analyzed by flow cytometry to detect long-term multilineage engraftment. Engraftment with human hematopoietic tissues was defined as >1% human CD45+ cells in the BM with human cells also detectable in the blood and spleen by flow cytometry. Engraftment data are stated in the text as mean ± standard deviation.

Human Colony-Forming Cell Assay
The colony-forming cell assay (CFU-C assay) was used to detect hematopoietic progenitor numbers. Cells were plated in at least duplicate for all independent experiments, and the mean score was used for analysis. All graphs show means of independent experiments, i.e., biological not technical variance, rounded to the nearest 5 CFU-Cs. To detect CFU-C number in dissociated human embryonic tissue, 0.1–0.005 ee of cells were plated into 1.5 mL of MethoCult H4034 Optimum Medium (STEMCELL Technologies) in 30 mm untreated tissue culture dishes. Cells were incubated at 37°C in 5% CO₂. Hematopoietic colonies were counted, scored, and photographed after 10–14 days.

Flow Cytometry
Antibody staining was performed in 5 mL polystyrene tubes (BD Falcon) or in U-bottomed 96-well plates (Sterilin). For flow cytometry analysis, the following mouse anti-human monoclonal antibodies were used: CD3-APC (clone SK7, eBioscience), CD4-APC (clone RPA-T4, BD Biosciences), CD8-PE (clone RPA-T8, BD Biosciences), CD14-APC (clone M5E2, BD Biosciences), CD19-PE (clone HIB19, eBioscience), CD33-PE (clone WM53, BD Biosciences), CD34-APC (clone 8G12, BD Biosciences), CD38-FITC (clone HIT2, BD Biosciences), CD45-FITC (clone H130, eBioscience), CD45RA-efluor450 (clone H1100, eBioscience),
prepared with cells, BD CompBeads Set Anti-Mouse Ig, except for one. In addition, single stains for each antibody were (fluorescence minus one), in which all antibodies were added to analysis. In parallel, control samples were stained with FMO 7-amino-actinomycin (7-AAD) (eBioscience) for flow cytometry in flow cytometry buffer supplemented with 1.5 mL of ice in the dark prior to two washes. Cells were resuspended in flow cytometry buffer supplemented with 1.5 µg/mL of 7-amino-actinomycin (7-AAD) (eBioscience) for flow cytometry analysis. In parallel, control samples were stained with FMO (fluorescence minus one), in which all antibodies were added except for one. In addition, single stains for each antibody were prepared with cells, BD CompBeads Set Anti-Mouse Ig (BD Biosciences) or UltraComp eBeads (eBioscience). Flow cytometry analysis was performed using a FACSCalibur (BD Bioscience) or BD LSR Fortessa analyzer (5 laser or 4 laser) (BD Bioscience). Compensation adjustments were made based on appropriate single stains, and gates were defined by FMO controls or isotype controls. Forward and side scatter profiles were used to assess cell size and granularity to gate cells of interest and exclude doublets. Live cells were gated according to low uptake of 7AAD. Flow cytometry data were analyzed with FlowJo v10.2 software (Tree Star).

SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.stemcr.2019.03.003.

AUTHOR CONTRIBUTIONS
J.E. designed and performed experiments, prepared the figures, and wrote the manuscript. S.R., S.G.-K, A.I., and S.T. also designed and performed experiments. A.M. supervised the experimental design and interpretation and wrote the manuscript. R.A.A. facilitated access to human embryos through the RAA/FT study.

ACKNOWLEDGMENTS
We thank the patients for donating tissue and A. Sauderson, J. Creiger, and N. Forson for gaining consent from patients and collecting specimens. We thank J. Verth, C. Manson, and their staff for animal maintenance. This work was supported by the Wellcome Trust (grant 100468/Z/12/Z, J.E.) and the MRC (grant G0901577, A.M.).

Received: December 21, 2018
Revised: March 9, 2019
Accepted: March 11, 2019
Published: April 4, 2019

REFERENCES


